QUEBEC, Nov. 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. today announced it will host an Investor and Analyst Day on Monday, November 21, 2005, from 1:30 p.m. - 4:00 p.m. ET, at The Fairmont Royal York Hotel in Toronto. The event will include presentations from the Company management, who will provide a corporate overview and an update on its broad product portfolio focused on oncology and endocrinology. In addition, several leading internal and external physician experts have been invited to speak about the opportunities for products currently under development, with a particular emphasis on cetrorelix, ozarelix (D-63153) and perifosine.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a growing global biopharmaceutical company engaged in the discovery, development and marketing of therapies for cancer and endocrine disorders.
AEterna Zentaris also owns 50.03% of Atrium Biotechnologies Inc. , a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries.
News releases and additional information are available at www.aeternazentaris.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.
AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations: Paul Burroughs, (418) 652-8525 ext. 406,paul.burroughs@aeternazentaris.com; Investor Relations: Ginette Vallieres,(418) 652-8525 ext. 265, ginette.vallieres@aeternazentaris.com; Europe:Matthias Seeber, +49 69 42602 3425, matthias.seeber@zentaris.com; Torequest a free copy of this organization’s annual report, please go tohttp://www.newswire.ca and click on reports@cnw.
